The original Health Economics Questionnaire (HEQ) is a comprehensive patient self-completed health economics questionnaire measuring health and social care resource use, medication, absenteeism from work and presenteeism, other productivity impacts as well as socio-demographic background information. It was developed in 2016 based on several years of international experience with within-trial (mental health) economic evaluations and originally implemented in the multi-country European PreDicT study.

Further language versions are also available in Dutch, French, German and Spanish.

User conditions HEQ

The use of the HEQ is free for non-commercial purposes and is conditional upon citation of the HEQ in any resulting work/publication as follows:  

• Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. DOI: 10.1186/s13063-017-2247-2

• Simon, J & Mayer, S (2016) HEQ (Health Economics Questionnaire), Version 08-09-2016, Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. https://doi.org/10.5281/zenodo.4559790

Download HEQ

For information, samples of the baseline and follow-up English language questionnaires can be viewed here: https://doi.org/10.5281/zenodo.4559790

Health Economics Questionnaire COVID-19
(HEQ COVID-19)

To allow for resource-use measurement in times of pandemics, the original Health Economics Questionnaire (HEQ) has been updated and complemented with a COVID-19 resource-use measurement module (Module 7) in 2020. The HEQ COVID-19 now both reflects the changed service provision landscape and having direct information on any COVID-19 related service use. In Module 7, a set of new questions have been added to capture further information about COVID-19 infections, self-isolation and related changes in health services use and employment status, with the purpose of understanding what resource use can be directly attributed to the on-going COVID-19 public health crisis rather than the investigated trial treatment or mental illness. The HEQ Covid-19 has been implemented in the UK-based PAX-BD and PAX-D studies.

Currently it is available in two languages: English, German.

User conditions HEQ COVID-19

The use of HEQ COVID-19 is available for non-commercial purposes   and is conditional upon citation of the HEQ in any resulting work/publication as follows:

• Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. DOI: 10.1186/s13063-017-2247-2

• Azim L, Hindmarch P, Browne G, Chadwick T, Clare E, Courtney P, Dixon L, Duffelen N, Fouweather T, Geddes J, Goudie N, Harvey S, Helter T, Holstein EM, Martin G, Mawson P, McCaffery J, Morriss M, Simon J, Smith D, Stokes PRA, Walker J, Weetman C, Wolstenhulme F, Young AH, Watson S, McAllister-Williams RH: Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). (submitted for publication)

• Simon, J & Mayer, S (2021): HEQ COVID-19 COVID-19, Version 24-02-2021, Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna. https://doi.org/10.5281/zenodo.4559752

Download HEQ COVID-19

For information, samples of the baseline and follow-up English language questionnaires can be viewed here: https://doi.org/10.5281/zenodo.4559752

Permission

Permission for any HEQ instrument use can be requested by e-mail at dhe@meduniwien.ac.at

Publications

• Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. DOI: 10.1186/s13063-017-2247-2

• Azim L, Hindmarch P, Browne G, Chadwick T, Clare E, Courtney P, Dixon L, Duffelen N, Fouweather T, Geddes J, Goudie N, Harvey S, Helter T, Holstein EM, Martin G, Mawson P, McCaffery J, Morriss M, Simon J, Smith D, Stokes PRA, Walker J, Weetman C, Wolstenhulme F, Young AH, Watson S, McAllister-Williams RH: Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). (submitted for publication)